The London Biotechnology Network presents: - OBN

echinoidclapΒιοτεχνολογία

1 Δεκ 2012 (πριν από 4 χρόνια και 8 μήνες)

247 εμφανίσεις

The London Biotechnology Network presents
:


“Genesis ”

The London Biotechnology Convention

11 December 2003

at the QE II Conference Centre, London


Delegate Fee £195






Exhibitor Fee from £200


*** UK’s largest one day biotechnology conference ***


Princ
ipal Sponsors


PricewaterhouseCoopers


IBM Life Sciences



Silver event sponsors


Antisoma : De Facto Communications : New Scientist Jobs


CMS Cameron McKenna : ITX Corporation


The third London Biotechnology Network Conference will again be held at the
QE II
conference centre and we expect another sell
-
out event with some 800 delegates and 80
exhibitors.


Just some of the companies already registered include :


Abingworth Management Limited

Ablynx

Affymetrix UK Ltd

Adrena BioCapital Ltd

Akos Healthc
are Group Ltd

Amersham plc

Antisoma plc

Apax Partners

Applied Enzyme Technology Ltd

Argenta Discovery

Arnold & Porter

Ashurst Morris Crisp

Arnold & Porter

Atlas Venture

Avidex Ltd

Avlar BioVentures

Barts and The London SMD

Bench International

Bidwells Science Innovations

Biocair International

BioIndustry Association

Biotechnology Investment Today

BioVex Ltd

Borolabs Ltd

Bovis Lend Lease Pharmaceutical Ltd

Bristows

BTG International

Business Link Surrey

Cancer Research Technology Limi
ted

Capital MSL

CB Hillier Parker

CereStem

Charles River UK Ltd

Citigroup

CMS Cameron McKenna

Critchley’s

CUH2A Europe Inc

deltaDOT

Department of Trade and Industry

Dowpharma

Drug Discovery Today

Eden Biopharm

Ernst & Young

Euro RSCG Life NR
P

First Filter Ltd

French Embassy

Geoffrey Osborne Ltd

GFA Ltd

GlaxoSmithKline

Hale & Dorr

Hunter Fleming

Huntleigh Technology Plc

IBA Associates

IBM

Icon Consulting

Imperial College Innovations

Inpharmatica

Institute of Cancer Research

Ioni
x Pharmaceuticals

ITX Corporation

Ipsen Ltd

J A Kemp & Co

John Wiley & Sons

Kilburn & Strode

King’s College London

Knowledgeable Transitional Services

KPMG

Lab Support UK

LGC

Lipoxen Technologies

London Bioscience Innovation Centre

Marix Drug
Development

Media Speak

MediCHIP

Medius Associates

Medpharm

Merlin Biosciences

MerseyBIO

Microscisnce Ltd

Microsens Biotechnologies

MRC Technology

National Institute for Medical Research

National Physical Laboratory

NCE Discovery

New England B
iolabs (UK) Ltd

New Scientist

Northrop Grumman Mission Systems

Novathera

Office of Health Economics

Onyvax Limited

Orgin Pharmaceutical Services

Osbourne

Oury Clark

PACE Group International Limited

Partnerships UK

PKF

Penn Pharmaceutical Servic
es Ltd

Pharmidex

Polytherics

Position Skane Inward Investment

PricewaterhouseCoopers

Propharma Partners Ltd

Proteome Sciences plc

Queen Mary University London

Scottish Equity Partners

Seebio

Sittingbourne Enterprise Hub

Simfonec

Springwell/Chap
elPharma

SpiroGen Limited

Steptoe & Johnson

Steve Harris Associates

SYBEN

Taylor Wessing

The Ann Hayes Consultancy Ltd

The Austin Company of UK Ltd

The School of Pharmacy, Uni of London

Trade Partners UK/ Bus Link Herts

Trigen Ltd

Turner & Towns
end

U S Bancorp Piper Jaffray

UCL Ventures

Vetter Pharma Fertigung

Wates Construction

Weil, Gotshal & Manges

Wolfson Institute for Biomedical Research

Wellcome Trust

Xenova Group Plc



Genesis offers a unique opportunity for exhibitors and delega
tes alike. Showcasing London’s
offering in terms of research/ commercial collaborations with the university medical schools
and existing London
-
based biotech companies, it is an ideal opportunity to forge links
between potential partners and investors.


Th
is year we are allocating at least 60% of the exhibition stands for biotech companies from
London and the rest of the UK and Europe and also encouraging more participation from the
biotechnology companies as delegates.


Concluding with a drinks reception a
nd a live
Blues Band
-

Genesis will be an ideal way to
start the festive season.



The Programme


9.30



Welcome by Chair


Simon Tarpey


9.35



Address by
Lord Sainsbury
, Minister for Science and Innovation


9.45



Technology Transfer


commercialising m
edical research

Dr Mark J Walport
,

Director

of the
Wellcome Trust,
opens our
conference programme of presentations at the origins of
biotechnology


discussing strategies for technology transfer in
medical research.





10.15



The Dealmaker

Antisoma

bro
kered the UK biotech deal of the year in 2002 with
Roche.
CEO Glyn Edwards

explains how to do deals


and then
make them work.


10:45



Coffee break
-

exhibitor visits and networking


11:30




Pharma 2010: The Threshold of Innovation


A report recently publ
ished by
IBM Business Consulting Services

predicts the birth of a new sort of blockbuster within the next eight
years.
Dr Nick Davies

will argue that a better understanding of the
molecular sciences, massive advances in computing power and
widespread recog
nition that the commercial potential of one
-
size
-
fits
-
all drugs is increasingly limited will collectively spur companies
into defining diseases much more precisely


and lead to the
development of healthcare packages for people with specific disease
subtyp
es
-

Targeted Treatment Solutions


12.0

Funding biotechnology in a bear market


Japanese corporation
ITX

have been funding UK and European
biotech companies over the last twelve months.

Dr Rami Suzuki,
Head of Life Sciences, Europe
,
explains why and
how they ar
e doing this in the current financial climate.



12:30



London Biotechnology Sector Opportunities




Honor Chapman CBE, Acting Chair, London Development Agency


12.45



Lunch

provided
-

exhibitor visits


14.00



Building a biotech product portfolio: from
bioterrorism to travel

vaccines

Dr John Brown
, CEO
Acambis


14.30

What Big Parma is looking for in biotech deals

Anthony S. Lubiniecki
,
Sc.D
.

VP, Biopharmaceutical Development
at
GlaxoSmithKline




15:00



Tea break


exhibitor visits


15.30

‘Ones to Watch’

-

6 presentations from emerging biotechnology
companies:

Chaired by Dr Ian Dixon, Director
PricewaterhouseCoopers

Life
Sciences Team and sponsored by
New Scientist Jobs
.



Microsens Biotechnologies

CEO Christopher Stanley

Pharmidex

CEO Alan Palmer

CereStem

C
EO Stephen Minger

Novathera

CEO Maureen Coleman

Medpharm

CEO Andy Muddle


16.30

Panel discussion with Ones to Watch presenters



17.00



Drinks/ networking with the Biotech Blues Band


17:00



The Network Hour with mellow jazz

18:00



The Party Hour with rhythm

and blues


19.00



Close



How to register



If you would like to register online now visit
http://www.one
-
events.com/register/



For further details, please contact Anita at One Events on +44 (0) 20 8767 5678 or email
anita@one
-
events.com